Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Epidermolysis Bullosa: early-phase trial registry
1 of 11 indexed Epidermolysis Bullosa trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 1 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Epidermolysis Bullosa: 11 US clinical trials tracked, 1 recruiting.
Epidermolysis Bullosa is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Abeona Therapeutics, running 3 of these trials.
Enrollment posture brief
Registry condition epidermolysis-bullosa
OPEN 1 | RECR 9% | LATE 3 | EARLY 8 | RANK #1577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Cancers (9% recruiting · 11 trials)
Epidermolysis Bullosa lists 1 open slots (9% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Epidermolysis Bullosa on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Epidermolysis Bullosa is recruiting below its size-band peers.
1 of 11 indexed trials (9.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Epidermolysis Bullosa research.
Abeona Therapeutics accounts for 3 of 11 trials (27.3%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Epidermolysis Bullosa trials plan to enrol fewer than 100 people.
Median target enrolment is 12 among the 11 trials that report a genuine target (sentinel values excluded). 11 of those (100%) plan for fewer than 100 participants.
-
Epidermolysis Bullosa research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
M. Peter Marinkovich
NCT06834035
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
Abeona Therapeutics
NCT05725018
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
RHEACELL GmbH & Co. KG
NCT05838092
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
Scioderm
NCT02014376
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
Masonic Cancer Center, University of Minnesota
NCT01033552
A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa
Stanford University
NCT03836001
Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution
Northwestern University
NCT05533866
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Jean Yuh Tang
NCT02654483
Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
Abeona Therapeutics
NCT01263379
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Abeona Therapeutics
NCT04227106
Study of Alwextin® Cream in Treating Epidermolysis Bullosa
Northwestern University
NCT00825565
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 4 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Epidermolysis Bullosa records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Epidermolysis Bullosa trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Epidermolysis Bullosa page
11 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Epidermolysis Bullosa trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Abeona Therapeutics sponsors the most Epidermolysis Bullosa trials on record, review their full trial history before evaluating a specific study. See Abeona Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Epidermolysis Bullosa condition card totals 11 registered trials; most-linked intervention EB-101; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.